Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
MiMedx Group ( (MDXG) ) has provided an announcement.
MiMedx Group reported a 3% increase in net sales for Q3 2024, reaching $84 million, driven by strong product contributions despite some sales team turnover and product declines. The company expects 2024 net sales growth to hit the high single digits, emphasizing strategic priorities and potential growth in placental tissue products. Adjusted EBITDA rose to $18 million, with a 22% margin, showcasing robust financial health amid market challenges.
Find detailed analytics on MDXG stock on TipRanks’ Stock Analysis page.
